Realm Therapeutics Plc (RLM) SEC Filing 6-K Foreign Issuer report for the period ending Tuesday, July 2, 2019

Realm Therapeutics Plc

CIK: 1718903 Ticker: RLM

View differences made from one to another to evaluate Realm Therapeutics Plc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Realm Therapeutics Plc.


Assess how Realm Therapeutics Plc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Realm Therapeutics Plc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Realm Therapeutics Plc provided additional information to their SEC Filing as exhibits

Ticker: RLM
CIK: 1718903
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001171843-19-004320
Submitted to the SEC: Tue Jul 02 2019 7:14:18 AM EST
Accepted by the SEC: Tue Jul 02 2019
Period: Tuesday, July 2, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: